Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit

Fierce Biotech
|
May 16, 2023
X min read
Fierce Biotech
|
May 16, 2023
Share on Social
share on Twitter or X
share on Linkedin
share onFacebook
share on Bluesky

More like this

Media

Another proof point from CIRM-supported research

October 7, 2026

California Institute for Regenerative Medicine

Read Now
Press

Another proof point from CIRM-supported research

October 7, 2026

California Institute for Regenerative Medicine

Read Now
Media

Can Geneticists Fight Disease by Targeting ‘Nurture’ Instead of ‘Nature’?

September 8, 2026

The New York Times

Read Now
Press

Can Geneticists Fight Disease by Targeting ‘Nurture’ Instead of ‘Nature’?

September 8, 2026

The New York Times

Read Now
Media

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

September 2, 2026

Read Now
Press

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

September 2, 2026

Read Now
See More